publication . Article . 2021

Favipiravir in Therapy of Viral Infections

Ryta Łagocka; Violetta Dziedziejko; Patrycja Kłos; Andrzej Pawlik;
Open Access
  • Published: 13 Jan 2021 Journal: Journal of Clinical Medicine, volume 10, page 273 (eissn: 2077-0383, Copyright policy)
  • Publisher: MDPI AG
Abstract
Favipiravir (FPV) is a novel antiviral drug acting as a competitive inhibitor of RNA-dependent RNA polymerase (RdRp), preventing viral transcription and replication. FPV was approved in Japan in 2014 for therapy of influenza unresponsive to standard antiviral therapies. FPV was also used in the therapy of Ebola virus disease (EVD) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, we discuss the mechanisms of action, pharmacokinetic parameters, toxicity, and adverse effects of FPV, as well as clinical studies evaluating the use of FPV in the therapy of influenza virus (IV) infection, EVD, and SARS-CoV-2 infection, along w...
Persistent Identifiers
Subjects
Medical Subject Headings: virusesvirus diseases
free text keywords: General Medicine, favipiravir, viral infection, influenza, Review, Antiviral drug, medicine.drug_class, medicine, Virus, RNA polymerase, chemistry.chemical_compound, chemistry, Adverse effect, Favipiravir, business.industry, business, Ebola virus, medicine.disease_cause, RNA, Disease, Virology, lcsh:Medicine, lcsh:R
Related Organizations
Any information missing or wrong?Report an Issue